The CRISPR‑PE Technology segmentation by application distinguishes four primary domains—Therapeutics, Agriculture, Industrial and Research—each driving a discrete share of the total market. Therapeutics, encompassing gene‑therapy interventions, disease‑model creation, and ex‑vivo cell editing, commands the largest revenue slice because of high clinical‑trial spend and premium pricing of personalized treatments. Agriculture captures a substantial portion through crop‑trait enhancement, livestock genome improvement, and stress‑resistance programs, where regulatory pathways are maturing and adoption rates are accelerating. Industrial use focuses on bio‑manufacturing, enzyme optimization, and bioremediation, contributing modest but growing revenues as companies seek sustainable production methods. The Research segment, while the smallest in monetary terms, underpins the ecosystem by generating data, protocols, and validation studies that expand downstream adoption across all other domains. Collectively, these application sub‑segments account for the full CRISPR‑PE market size, with their relative weight reflected in the accompanying pie‑chart. Projected CAGR of 28% through 2032 reinforces the proportional impact of each domain, as capital allocation follows clinical success in therapeutics and policy incentives in agriculture.